EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial

Beeinflusst die Anwendung von Benzodiazepinen die Wirksamkeit von Lifestyle-Interventionen? Sekundäranalyse der SPRINTT-Studie

Elena Levati iD, Maria Beatrice Zazzara, Daniele Giuli iD, Emanuele Marzetti, Anna Picca, Riccardo Calvani, Matteo Tosato iD, Francesco Landi, Roberto Bernabei, Graziano Onder

Age and Ageing · 03.08.2026 · 55 (8)

DOI: 10.1093/ageing/afag257 ↗

Auf einen Blick

In einer Sekundäranalyse der SPRINTT-Studie war die Wirkung der multikomponentigen Intervention auf Mobilitätsbehinderung bei Benzodiazepin-Nutzer:innen im SPPB-Subgruppenbereich 3 bis 7 nicht nachweisbar.

Fragestellung

Beeinflusst Benzodiazepin-Gebrauch die Wirksamkeit einer Lifestyle-Intervention zur Vermeidung von Mobilitätsbehinderung bei älteren Menschen?

Methode

Sekundäranalyse der SPRINTT-Studie; Lifestyle-Intervention mit körperlichem Training und Ernährungsberatung; Cox-Regression; getrennte Analyse für SPPB 3 bis 7.

Ergebnisse

1506 Teilnehmende, mittleres Alter 78,9 Jahre, 71,5 % Frauen; 211 (14,0 %) mit Benzodiazepinen zu Baseline. SPPB 3 bis 7: nur bei Nicht-Nutzer:innen Effekt der MCI (HR 0,80; 95 %-KI 0,66–0,97 bzw. 0,79; 95 %-KI 0,64–0,96), nicht bei Nutzer:innen (HR 1,06; 95 %-KI 0,65–1,71 bzw. 1,13; 95 %-KI 0,60–2,13).

Schlussfolgerung der Autor:innen

Bei gebrechlichen älteren Erwachsenen schwächt Benzodiazepin-Gebrauch nach Angaben der Autor:innen die Wirksamkeit von Lifestyle-Interventionen zur Prävention von Mobilitätsbehinderung deutlich ab.

Kernaussagen

  • 1506 Teilnehmende; 211 (14,0 %) nutzten Benzodiazepine zu Baseline
  • Im SPPB-Subgruppenbereich 3 bis 7 nur bei Nicht-Nutzer:innen ein Effekt der MCI
  • Bei Nutzer:innen zeigte sich kein Zusammenhang mit der MCI

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 02.09.2026. Verfasst von Elena Levati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome 00168, Italy. Hauptthemen laut MEDLINE: Benzodiazepines, Sarcopenia, Frailty, Frail Elderly. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Benzodiazepine use is prevalent among older adults despite its recognised negative effects, including increased risk of falls, fractures and decline in functional status. Lifestyle interventions can preserve physical function and reduce the risk of disability. This study investigates whether benzodiazepine use reduces the effectiveness of lifestyle-based interventions on mobility disability.

Methods

We performed a secondary analysis of the ‘Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies’ trial. The lifestyle intervention consisted of physical exercise and nutritional counselling. Benzodiazepine use was assessed based on baseline or longitudinal exposure (defined as use at baseline plus use at two or more additional time points). Cox regression models were used to ascertain the association between benzodiazepine use and mobility disability incidence. A separate analysis was conducted among participants with a Short Physical Performance Battery (SPPB) score 3 to 7.

Results

Among the 1506 participants included (mean age 78.9 years; 71.5% female; 753 intervention vs. 753 control), 211 (14.0%) reported benzodiazepine use at baseline. Overall, 55.0% of baseline benzodiazepine users and 43.6% of non-users developed mobility disability during the follow-up (P = .003). When baseline benzodiazepine use was considered, no significant effect associated with multicomponent intervention (MCI) was shown among non-users (Hazard Ratio (HR) = 0.86; 95% Confidence Interval (CI) 0.72–1.03) and users (HR = 1.04; CI 0.67–1.62). In the subgroup of participants with SPPB scores 3 to 7, a significant effect of the MCI was observed only among non-users (HR = 0.80, 95% CI 0.66–0.97), while no ‘association’ was detected among users (HR = 1.06; 95% CI 0.65–1.71, P for interaction = .035). When longitudinal benzodiazepine exposure was considered, similar results were observed. In particular, in the SPPB score 3 to 7 subgroup, the beneficial effect of the MCI was observed only among non-users (HR = 0.79; 95% CI 0.64–0.96), while no ‘association’ was detected among users (HR = 1.13; 95% CI 0.60–2.13, P for interaction = .035).

Conclusion

In frail older adults, benzodiazepine use significantly blunts the effectiveness of lifestyle interventions for preventing mobility disability. These findings support a prudent approach to benzodiazepine use in frail older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesSarcopeniaFrailtyFrail ElderlyLife StyleRisk Reduction BehaviorExercise TherapyHumansFemaleAgedMaleMobility LimitationAged, 80 and overDisability EvaluationRisk FactorsGeriatric AssessmentTreatment OutcomeTime Factors

Stichwörter der Autor:innen

benzodiazepinesexerciselifestyle interventionmobility disabilityolder people

Substanzen

Benzodiazepines

Autor:innen und Institutionen

  • Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome 00168, Italy.
  • Department of Aging, Orthopaedics and Rheumatological Sciences, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
  • Department of Medicine and Surgery, LUM University, Casamassima, Italy.
  • Italialongeva, Rome, Italy.

ORCID-Profile: Elena Levati, Daniele Giuli, Matteo Tosato

Zitieren

APA

Levati, E., Zazzara, M. B., Giuli, D., Marzetti, E., Picca, A., Calvani, R., Tosato, M., Landi, F., Bernabei, R., & Onder, G. (2026). Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag257

Vancouver

Levati E, Zazzara MB, Giuli D, Marzetti E, Picca A, Calvani R, et al. Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag257

BibTeX
@article{Levati2026,
  author = {Levati, Elena and Zazzara, Maria Beatrice and Giuli, Daniele and Marzetti, Emanuele and Picca, Anna and Calvani, Riccardo and Tosato, Matteo and Landi, Francesco and Bernabei, Roberto and Onder, Graziano},
  title = {Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {8},
  doi = {10.1093/ageing/afag257}
}
Kostenlos starten →